ReviewJournal of clinical medicine2020
Early Intervention in Ulcerative Colitis: Ready for Prime Time?
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 46 citations in OpenAlex.
- Predictive Utility of the Vedolizumab Clinical Decision Support Tool in a Real-World IBD Cohort: Differential Performance in Crohn's Disease and Ulcerative Colitis.Medicina (Kaunas, Lithuania) · 2026Article
- A real-world observational study of second-line anti-TNFα treatment in patients with ulcerative colitis who received vedolizumab as a first-line biologic.Crohn's & colitis 360 · 2026Article
- Anti-Inflammatory Effects of Marine-Derived Resorcylic Acid Lactone Derivatives in Ulcerative Colitis via the MAPK/ERK Pathway.Marine drugs · 2026Article
- Clinical Efficacy of Early and Late Vedolizumab or Infliximab Interventions in Moderate Ulcerative Colitis: A Multicenter, Retrospective Cohort Study.Gastroenterology research · 2026Article
- Patterns of conventional therapy use and advanced therapy initiation drivers in inflammatory bowel disease.Therapeutic advances in gastroenterology · 2026Article
- Vedolizumab in biologic-naïve ulcerative colitis: a multicenter real-world evaluation of clinical benefits and exploratory inflammatory indices.Frontiers in medicine · 2026Article
- From guidelines to evidence-based practice - A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis.Zeitschrift fur Gastroenterologie · 2025Review
- Explainable artificial intelligence for personalized management of inflammatory bowel disease: A minireview of recent advances.World journal of gastroenterology · 2025Review
- Disease Clearance in Ulcerative Colitis: A Narrative Review.United European gastroenterology journal · 2025Review
- FastColitisDetector-XAI: An efficient AI model utilizing sparse Autoencoder with explainable AI for ulcerative colitis diagnosis.MethodsX · 2025Article
- Identification of ulcerative colitis diagnostic markers from differentially expressed genes shared with Hirschsprung disease.Scientific reports · 2025Article
- Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease.Journal of clinical medicine · 2025Review
- The ability of C-reactive protein-albumin ratio to predict disease activity in ulcerative colitis.Biomarkers in medicine · 2025Article
- Real-World Treatment Outcomes Associated With Early Versus Delayed Vedolizumab Initiation in Patients With Ulcerative Colitis.Crohn's & colitis 360 · 2024Article
- Change in systemic steroid use and surgery rate in patients with inflammatory bowel disease: a Japanese real-world database analysis.Journal of gastroenterology · 2024Article
- Drug Optimization in Patients with Mild-to-Moderate Ulcerative Colitis: A Global Survey.Journal of clinical medicine · 2024Article
- Current Approaches for Monitoring of Patients with Inflammatory Bowel Diseases: A Narrative Review.Journal of clinical medicine · 2024Review
- Access to High-Cost Biological Agents: Perceptions of Brazilian Patients with Inflammatory Bowel Diseases.Journal of clinical medicine · 2023Article
- Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance.Nature reviews. Gastroenterology & hepatology · 2023Article
- Intestinal complications in Brazilian patients with ulcerative colitis treated with conventional therapy between 2011 and 2020.World journal of gastroenterology · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing evidence shows that ulcerative colitis (UC) is a progressive disease similar to Crohn's disease (CD). The UC-related burden is often underestimated by physicians and a standard step-up therapeutic approach is preferred. However, in many patients with UC the disease activity is not adequately controlled by current management, leading to poor long-term prognosis. Data from both randomized controlled trials and real-world studies support early intervention in CD in order to prevent disease progression and irreversible bowel damage. Similarly, an early disease intervention during the so-called "window of opportunity" could lead to better outcomes in UC. Here, we summarize the literature evidence on early intervention in patients with UC, highlighting strengths and limitations of this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.